Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495338 · ClinicalTrials.gov registry record · Phase 1
A Comparison of the Safety and Comfort of AC-170
A Phase 1 study, sponsored by Aciex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01495338 is a Phase 1 study that has completed, run by Aciex Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT01495338, a Phase 1 study, has completed, sponsored by Aciex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.
Interventions
- DRUG AC-170 0.17%
- DRUG AC-170 0.24% (Formulation 1)
- DRUG AC-170 0.24% (Formulation 2)
- DRUG Olopatadine hydrochloride 0.2%/Tears Naturale II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495338
The ClinicalTrials.gov registry entry for NCT01495338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aciex Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AC-170 0.17% is the first listed.
NCT01495338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01495338 about?
NCT01495338 is a clinical study titled "A Comparison of the Safety and Comfort of AC-170". The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.
What is the current status of trial NCT01495338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01495338?
The interventions under investigation include: AC-170 0.17% (DRUG), AC-170 0.24% (Formulation 1) (DRUG), AC-170 0.24% (Formulation 2) (DRUG), Olopatadine hydrochloride 0.2%/Tears Naturale II (DRUG).
Who is sponsoring clinical trial NCT01495338?
This trial is sponsored by Aciex Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.